• Harrow agreed to acquire global rights to TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris.
• Deal terms include USD 30 million cash at closing, up to USD 70 million in net-sales milestones; total consideration up to USD 100 million.
• Closing is expected in the second half of 2026, subject to customary conditions; the upfront payment is expected to be funded with cash on hand.
• TYRVAYA is indicated for dry eye disease, complementing Harrow’s VEVYE franchise with a nasal-spray option that avoids eye-drop instillation reactions.
• TYRVAYA is approved in the U.S., China, and Taiwan; additional marketing applications are pending in other countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.